402 related articles for article (PubMed ID: 17724833)
1. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
5. Imatinib: new indication. Efficacy in gastrointestinal stromal tumours must be confirmed.
Prescrire Int; 2003 Oct; 12(67):163-4. PubMed ID: 14610781
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
7. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
8. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
10. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
12. [Strategy for patients with GIST after failure of imatinib].
Abe S; Kubota T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):540-3. PubMed ID: 19381023
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
15. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Cohen MH; Farrell A; Justice R; Pazdur R
Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
[TBL] [Abstract][Full Text] [Related]
18. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
Yoon SS; Tanabe KK
Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951
[No Abstract] [Full Text] [Related]
19. Imatinib: new indication. Chronic myeloid leukaemia, first-line option: favourable findings to be confirmed.
Prescrire Int; 2003 Dec; 12(68):216-8. PubMed ID: 14986692
[TBL] [Abstract][Full Text] [Related]
20. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
